Bio-Rad Laboratories, Inc. (BIO)

Bio-Rad Laboratories Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	403.82	434.22	470.78	662.21	660.67
Short-Term Investments	1,209	1,362	404.7	334.47	459.53
Cash & Cash Equivalents	1,613	1,796	875.48	996.68	1,120
Cash Growth	-10.22%	105.17%	-12.16%	-11.03%	31.73%
Receivables	489.02	494.65	423.54	419.42	392.67
Inventory	780.52	719.32	572.24	622.25	554.01
Other Current Assets	166.09	147.78	119.23	101.48	113.27
Total Current Assets	3,048	3,158	1,990	2,140	2,180
Property, Plant & Equipment	723.74	679.56	716.44	693.51	701.21
Long-Term Investments	7,698	8,831	14,387	9,561	4,638
Goodwill and Intangibles	734.08	738.64	601.28	491.41	409.66
Other Long-Term Assets	94.85	94.6	104.19	86.72	79.64
Total Long-Term Assets	9,251	10,344	15,809	10,833	5,829
Total Assets	12,299	13,502	17,799	12,973	8,009
Accounts Payable	144.63	135.04	141.94	139.45	107.01
Deferred Revenue	0	0	50.85	42.47	33.74
Current Debt	40.87	36.8	36.92	38.31	461.54
Other Current Liabilities	337.31	396.87	451.22	411.31	303.21
Total Current Liabilities	522.8	568.71	680.94	631.54	905.5
Long-Term Debt	1,365	1,351	186.45	187.39	189.6
Other Long-Term Liabilities	1,671	1,966	3,247	2,274	1,159
Total Long-Term Liabilities	3,035	3,318	3,433	2,461	1,348
Total Liabilities	3,558	3,886	4,114	3,093	2,254
Total Debt	1,405	1,388	223.38	225.69	651.13
Debt Growth	1.24%	521.42%	-1.03%	-65.34%	48.18%
Retained Earnings	9,261	9,898	13,525	9,268	5,471
Comprehensive Income	-336.04	-466.82	-175.55	282.46	-87.35
Shareholders' Equity	8,741	9,615	13,685	9,880	5,755
Net Cash / Debt	207.31	408.12	652.1	770.99	469.07
Net Cash / Debt Growth	-49.20%	-37.42%	-15.42%	64.36%	14.15%
Net Cash Per Share	7.10	13.70	21.59	25.56	15.54
Working Capital	2,526	2,589	1,310	1,508	1,275
Book Value Per Share	299.26	322.82	458.76	331.90	192.84

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).